Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis
Authors' conclusion
Once-daily semaglutide 7 and 14 mg can significantly lowered HbA1c and body weight in patients with T2DM, and this effect increases with dose. Significantly, more gastrointestinal events occurred with semaglutide 14 mg.
Study context
- Population
- Patients with T2D in randomized controlled trials (RCTs) of oral semaglutide, from inception through May 31, 2021
- Participants
- 9,821 patients11 RCTs
- Comparison
- Oral semaglutide 7 and 14 mg vs placebo or other antidiabetic agents
- Outcome
- Change from baseline in HbA1c and body weight
Pooled result
As reported in the abstract
Change in HbA1c
- Semaglutide 7 mg vs Placebo · lower with semaglutide 7 mg
- Hemoglobin A1c (HbA1c) reduction 1.06 % (95% CI 0.81–1.30)
- Semaglutide 14 mg vs Placebo · lower with semaglutide 14 mg
- HbA1c reduction 1.10 % (95% CI 0.88–1.31)
- Semaglutide 7 mg vs Other antidiabetic agents · lower with semaglutide 7 mg
- HbA1c reduction 0.26 % (95% CI 0.15–0.38)
- Semaglutide 14 mg vs Other antidiabetic agents · lower with semaglutide 14 mg
- HbA1c reduction 0.38 % (95% CI 0.31–0.45)
Safety
- Semaglutide 14 mg increased the incidence of medication discontinuation and gastrointestinal events (nausea, vomiting and diarrhea)
Original publication
Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. Published 5 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →